What kind of therapeutic solutions for Graves’ disease does modern medicine propose? - a review of the literature
Authors:
- Natalia WośNWNatalia Woś
- Karolina Szala-CzerwonkaKSKarolina Szala-Czerwonka
- Adrian RejmerARAdrian Rejmer
- Katarzyna RojekKRKatarzyna Rojek
- Lucjan BednarzLBLucjan Bednarz
- Karolina WijasKWKarolina Wijas
- Kinga BialicKBKinga Bialic
- Rafał BakalarczykRBRafał Bakalarczyk
- Artur BialicABArtur Bialic
- Paweł MajewskiPMPaweł Majewski
Open Access
- 20 May 2023
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 32 (1) , 31-46
Abstract
Background: Graves' disease is responsible for 60-80% causes of hyperthyreosis. An important role in the pathogenesis is played by anti-TSHR immunoglobulins (TRAb), that stimulate TSH receptors leading to excessive hormone synthesis and release by the gland. The aim of the study: This study was designed to summarise the current state of knowledge on the diagnosis, pathogenesis and methods of treatment used for Graves' disease. Materials and methods: We reviewed the literature available in the PubMed database using the following keywords: "Graves' disease", "Graves' pathogenesis", "Graves' diagnosis", "Graves' treatment”. Results: Graves' disease develops as a result of as well genetic as environmental factors. The diagnosis is based on physical examination, and laboratory & imaging studies. Several therapeutic options are currently used. Pharmacotherapy with thyreostatics is used either as a stand-alone method or as a preparation for a radical treatment - radioactive iodine ablation and thyroidectomy, which is the surgical removal of the gland. The treatment form is recommended to be selected individually depending on each patient, indications and co-morbidities. Developing research into the etiology of the disease is an opportunity to develop newer and efficient methods of causal treatment. Summary: Graves' disease is an autoimmune thyroid disorder with a multiple factor etiology. A variety of therapeutic approaches are currently used: treatment with antithyrodid drugs, radioactive iodine ablation and the surgical resection of the thyroid gland. A more detailed understanding of the mechanisms causing the development of the disease offers prospects for the creation of innovative and more efficient therapeutic modalities.Keywords
This publication has 28 references indexed in Scilit:
- Hypocalcemia following total and subtotal thyroidectomy and associated factorsAnnals of Medicine & Surgery, 2021
- Management of Graves Thyroidal and Extrathyroidal Disease: An UpdateThe Journal of Clinical Endocrinology & Metabolism, 2020
- New Therapeutic Horizons for Graves’ HyperthyroidismEndocrine Reviews, 2020
- Should radioiodine now be first line treatment for Graves’ disease?Thyroid Research, 2020
- Considerations for Thyroidectomy as Treatment for Graves DiseaseClinical Medicine Insights: Endocrinology and Diabetes, 2019
- Marine-Lenhart Syndrome: Case Report, Diagnosis, and ManagementCase Reports in Endocrinology, 2018
- Recurrent Graves’ hyperthyroidism after prolonged radioiodine-induced hypothyroidismTherapeutic Advances in Endocrinology and Metabolism, 2017
- Epidemiology, management and outcomes of Graves’ disease—real life dataEndocrine, 2017
- HyperthyroidismThe Lancet, 2016
- Patient Knowledge of Antithyroid Drug-Induced AgranulocytosisEuropean Thyroid Journal, 2014